Blog

Integrated Protein Production: Where Program Time Actually Goes

Integrated Protein Production: Where Program Time Actually Goes Integrated protein production moved up the buyer agenda this fall. On October 12, 2026, Research and Markets projected that the contract manufacturing and research services market will grow from $303.8 billion in 2026 to $472.1 billion by 2033. That summary credits integrated services with shorter timelines. Consequently, … Continue reading Integrated Protein Production: Where Program Time Actually Goes

Cell Bank Resilience as Biomanufacturing Becomes Critical Infrastructure

Cell Bank Resilience as Biomanufacturing Becomes Critical Infrastructure Cell bank resilience entered the policy conversation this fall. On September 24, 2026, lawmakers introduced the Protecting Biotechnology and Biomanufacturing as Critical Infrastructure Act (H.R. 10569). The bill would direct the Cybersecurity and Infrastructure Security Agency to protect biomanufacturing infrastructure. Consequently, buyers are asking sharper questions about … Continue reading Cell Bank Resilience as Biomanufacturing Becomes Critical Infrastructure

Efficient Cell Line Development as Biotech Capital Concentrates

Efficient Cell Line Development as Biotech Capital Concentrates Efficient cell line development is now a budgeting question as much as a scientific one. J.P. Morgan’s Q3 2026 biopharma and medtech deal report, published October 20, puts biopharma venture funding at $23.9 billion across 385 rounds year to date. Funding moderated in the third quarter, and … Continue reading Efficient Cell Line Development as Biotech Capital Concentrates

CHO Cell Glycosylation: What New Engineering Data Means for Cell Line Development

CHO Cell Glycosylation: What New Engineering Data Means for Cell Line Development CHO cell glycosylation shapes how a therapeutic protein behaves in the body. Glycan structures influence half-life, effector function, and immunogenicity. Therefore small shifts in a culture can move a product’s quality profile. A review in Frontiers in Bioengineering and Biotechnology, published in August … Continue reading CHO Cell Glycosylation: What New Engineering Data Means for Cell Line Development

ADC Cell Line Development: Building the Antibody Behind an Antibody-Drug Conjugate

ADC Cell Line Development: Building the Antibody Behind an Antibody-Drug Conjugate Antibody-drug conjugates remain one of the hottest areas in oncology. As of June 30, 2026, 23 ADCs had regulatory approval worldwide. In addition, China approved izalontamab brengitecan on June 22, 2026, reported as the first approved bispecific ADC. Payloads and linkers get most of … Continue reading ADC Cell Line Development: Building the Antibody Behind an Antibody-Drug Conjugate